Oxurion NV (GB:0G99) has released an update.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Oxurion NV, a Belgian biopharmaceutical company, is in exclusive talks to acquire an 80% stake in a French CRO specializing in stem cell production, with the deal potentially valued at €12.23 million. This strategic move aims to diversify Oxurion’s R&D-focused business and add a profitable, rapidly growing entity to its assets. The acquisition, expected to complete by October 2024, will be financed through a mix of debt and possibly dilutive shareholder financing.
For further insights into GB:0G99 stock, check out TipRanks’ Stock Analysis page.
